Summit Financial LLC Has $7.50 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Summit Financial LLC lowered its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 17.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 10,532 shares of the biopharmaceutical company’s stock after selling 2,250 shares during the quarter. Summit Financial LLC’s holdings in Regeneron Pharmaceuticals were worth $7,503,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. D.A. Davidson & CO. boosted its holdings in shares of Regeneron Pharmaceuticals by 5.1% in the 3rd quarter. D.A. Davidson & CO. now owns 821 shares of the biopharmaceutical company’s stock valued at $863,000 after buying an additional 40 shares during the last quarter. Quantbot Technologies LP bought a new stake in Regeneron Pharmaceuticals during the third quarter worth $151,000. Public Sector Pension Investment Board lifted its stake in Regeneron Pharmaceuticals by 13.0% in the third quarter. Public Sector Pension Investment Board now owns 4,341 shares of the biopharmaceutical company’s stock valued at $4,563,000 after acquiring an additional 500 shares during the last quarter. Hantz Financial Services Inc. grew its position in shares of Regeneron Pharmaceuticals by 87.2% in the 3rd quarter. Hantz Financial Services Inc. now owns 73 shares of the biopharmaceutical company’s stock valued at $77,000 after acquiring an additional 34 shares during the period. Finally, Captrust Financial Advisors increased its stake in shares of Regeneron Pharmaceuticals by 3.4% during the 3rd quarter. Captrust Financial Advisors now owns 9,130 shares of the biopharmaceutical company’s stock worth $9,597,000 after purchasing an additional 296 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 0.2 %

Shares of NASDAQ:REGN opened at $637.36 on Monday. The firm has a market cap of $69.68 billion, a P/E ratio of 16.65, a P/E/G ratio of 2.34 and a beta of 0.27. Regeneron Pharmaceuticals, Inc. has a 12-month low of $629.02 and a 12-month high of $1,211.20. The business has a fifty day simple moving average of $683.88 and a 200 day simple moving average of $795.57. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $11.86 earnings per share. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were given a $0.88 dividend. The ex-dividend date was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.55%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 2.30%.

Wall Street Analyst Weigh In

A number of research firms recently commented on REGN. Bank of America reiterated an “underperform” rating and set a $565.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. Sanford C. Bernstein decreased their target price on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. Bernstein Bank cut their price target on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. TD Cowen decreased their price objective on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a report on Tuesday, February 4th. Finally, Canaccord Genuity Group started coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price for the company. One investment analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.